

# **Examination of Pancreatic Transdifferentiation in the Livers of Animals**

**by Que Tran La**

Thesis submitted in fulfilment of the requirements for the  
degree of

**Doctor of Philosophy**

under the supervision of:  
Professor Ann M. Simpson and  
Doctor Najah T. Nassif

University of Technology Sydney  
Faculty of Science

March 2021

# CERTIFICATE OF ORIGINAL AUTHORSHIP

I, Que Tran La declare that this thesis, is submitted in fulfilment of the requirements for the award of Doctor of Philosophy, in the School of Life Sciences at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise referenced or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research was supported by an NHMRC grant (APP1086256, Simpson, Alexander, O'Brien) and by the Australian Government Research Training Program Scholarship.

Signature:

Production Note:  
Signature removed prior to publication.

Date: 26/03/2021

# Acknowledgements

Firstly, I would like to thank my supervisors Prof. Ann Simpson and Dr. Najah Nassif for their guidance and support throughout the duration of my PhD studies. I am very grateful for the opportunities to develop my knowledge and skills in the field of gene therapy under their guidance. I would like to especially thank Dr. Binhai Ren (UTS) for performing the FFO surgeries, an important part of my experiments as well as A/ Prof. Bronwyn O'Brien for her helpful advice on my experiments. I would also want to show my appreciation to Prof. Ian Alexander, Dr. Grant Logan, Dr. Sharon Cunningham and Ms Neeta Khandekar [Children's Medical Research Institute (CMRI), Westmead] for producing the AAV8 vectors that were used in my experiments. I would also like to thank the staff of the Ernst Facility, who have assisted me in monitoring and caring for the animals and especially Ms Fiona Ryan and Ms Lalit Overlunde for coaching me in the aspects of animal care. I would like to thank all the laboratory and administrative staff at the School of Life Sciences, especially Ms Sarah Osvath and Ms Shannon Hawkins for their assistance. Finally, I would like to thank my fellow colleagues of the Simpson group and my friends for their support over the years.

# List of Publications

1. La, Q.T., Ren, B., Logan, G.J., Cunningham, S.C., Khandekar, N., Nassif, N.T., O'Brien, B.A., Alexander, I.E., and Simpson, A.M., *Use of a Hybrid Adeno-Associated Viral Vector Transposon System to Deliver the Insulin Gene to Diabetic NOD Mice*. *Cells*, 2020. **9**(10): p. 2227.
2. Ren, B., La, Q.T., O'Brien, B.A., Nassif, N.T., Tan, Y., Gerace, D., Martiniello-Wilks, R., Torpy, F., Dane, A.P., Alexander, I.E., and Simpson, A.M., *Partial pancreatic transdifferentiation of primary human hepatocytes in the livers of a humanised mouse model*. *The Journal of Gene Medicine*, 2018. **20**(5): p. e3017.

# List of Presentations

1. La, Q.T., Ren, B., Logan, G.J., Cunningham, S.C., Khandekar, N., Nassif, N.T., O'Brien, B.A., Alexander, I.E., and Simpson, A.M., D The reversal of diabetes in non-obese-diabetes (NOD) mice using adeno associated viral vector (AAV) and furin-cleavable human insulin (*INSFUR*) gene . In: Australasian Diabetes Congress, Sydney, 2019.
2. La, Q.T., Ren, B., Logan, G.J., Cunningham, S.C., Khandekar, N., Nassif, N.T., O'Brien, B.A., Alexander, I.E., and Simpson, A.M., Delivery of The Insulin gene Using an Integrating Adeno-Associated Viral Vector (AAV) to Diabetic NOD mice. In: The American Diabetes Association Scientific 79<sup>th</sup> Scientific Session, San Francisco, USA, 2019.
3. La, Q.T., Ren, B., O'Brien, B.A., Nassif, N.T., Alexander, I.E, and Simpson, A.M., Reversal of diabetes in a humanised mouse model. In: Australasian Cell and Gene Therapy Society Biannual Meeting, Sydney, Australia, 2017.
4. La, Q.T., Ren, B., O'Brien, B.A., Nassif, N.T., Alexander, I.E, and Simpson, A.M., Pancreatic transdifferentiation in the livers of a humanised mouse model engineered to express insulin. In: New Horizons Conference, Sydney, Australia, 2015.

# **Format of the Thesis**

This is a thesis by compilation. The first chapter is the introduction to the research study and the review of the literature. Chapter 2 describes the experiments, general materials and methods, followed by chapter 3, 4 and 5 showing detailed methods, results and the discussion of each subset of experiments. Chapter 4 is a published peer reviewed journal article. The last chapter of this thesis is the general discussion and the recommendation for future studies.

# Publication Included in the Thesis

**Title:** Use of a Hybrid Adeno-Associated Viral Vector Transposon System to Deliver the Insulin Gene to Diabetic NOD Mice

**Authors:** Que T. La <sup>1,2</sup>, Binhai Ren <sup>1,2</sup>, Grant Logan <sup>3</sup>, Sharon C. Cunningham <sup>3</sup>, Neeta, Khandekar <sup>3</sup>, Najah T. Nassif <sup>1,2</sup>, Bronwyn A. O'Brien <sup>1,2</sup>, Ian E. Alexander <sup>3,4</sup> and Ann M. Simpson<sup>1,2</sup>

<sup>1</sup> School of Life Sciences, University of Technology Sydney, 15 Broadway, Ultimo NSW 2007, Australia

<sup>2</sup> Centre for Health Technologies, University of Technology Sydney, 15 Broadway, Ultimo NSW 2007, Australia

<sup>3</sup> Gene Therapy Research Unit, Children's Medical Research Institute and Sydney Hospitals Network, University of Sydney, 214 Hawkesbury Rd, Westmead NSW 2145, Australia;

<sup>4</sup> Discipline of Child and Adolescent Health, University of Sydney, Crn Hainsworth and Hawkesbury Rd, Westmead NSW 2145, Australia

**Journal:** Cells; **Issue:** 10

**Received:** 03 August 2020; **Accepted:** 30 September 2020; **Published:** 2 October 2020

# Author Contributions

Ann M. Simpson<sup>1</sup>, Ian E. Alexander<sup>3,4</sup>, and Bronwyn A. O'Brien<sup>1,2</sup> initiated the concept of this study and secured funding.

Ann M. Simpson<sup>1</sup> and Que T. La<sup>1,2</sup> wrote the draft article and all authors contributed to review of the final article and editing.

Binhai Ren<sup>1,2</sup> produced the lentiviral vector and with Que T. La<sup>1,2</sup>, contributed to experimental design, performed the animal experiments, immunohistochemistry, RT-PCR analysis and data analysis.

Grant Logan<sup>3</sup> designed the AAV vectors, contributed to experimental design and performed data analysis.

Sharon C. Cunningham<sup>3</sup> designed the AAV/*piggyBac* vectors and contributed to experimental design and data analysis.

Neeta, Khandekar<sup>3</sup> produced the AAV vectors and performed VCN and data analysis.

Najah T. Nassif<sup>1,2</sup> contributed to the experimental design and performed primer design and data analysis.

Bronwyn A. O'Brien<sup>1,2</sup> contributed to experimental design and data analysis.

All authors contributed to the interpretation of the data.



### Signatures of the authors

Name	Signature
Que T. La	Production Note: Signature removed prior to publication.
Dr. Binhai Ren	Production Note: Signature removed prior to publication.
Dr. Grant Logan <sup>3</sup>	Production Note: Signature removed prior to publication.
Dr. Sharon C. Cunningham <sup>3</sup>	Production Note: Signature removed prior to publication.
Ms Neeta, Khandekar <sup>3</sup>	Production Note: Signature removed prior to publication.
Dr. Najah T. Nassif <sup>112</sup>	Production Note: Signature removed prior to publication.
A.Prof. Bronwyn A. O'Brien	Production Note: Signature removed prior to publication.
Prof. Ian E. Alexander <sup>314</sup>	Production Note: Signature removed prior to publication.
Prof. Ann M. Simpson	Production Note: Signature removed prior to publication.

# Table of Contents

	<b>Page</b>
<b>Certificate of Original Authorship</b>	i
<b>Acknowledgment</b>	ii
<b>List of Publications</b>	iii
<b>List of Presentations</b>	iv
<b>Format of the Thesis</b>	v
<b>Publication Included in the Thesis</b>	vi
<b>Author Contributions</b>	vii
<b>Table of Contents</b>	ix
<b>List of Figures and Tables</b>	xv
<b>List of Abbreviations</b>	xxii
<b>Abstract</b>	xxvii
<b>Chapter1: Introduction</b>	1
<b>1.1 Introduction</b>	2
<b>1.2 Overview of insulin synthesis, storage, release and mechanism of action</b>	4
<b>1.3 The roles of pancreatic transcription factors in the development of pancreatic <math>\beta</math>-cells</b>	8
1.3.1 Forkhead box A2 ( <i>Foxa2</i> )	12
1.3.2 Pancreatic specific transcription factor 1 ( <i>Ptf1</i> )	13
1.3.3 Pancreatic duodenal homeobox1( <i>Pdx1</i> )	13
1.3.4 Neurogenin3 ( <i>Ngn3</i> )	14
1.3.5 Neuronal differentiation 1 ( <i>NeuroD1</i> )	15
1.3.6 Paired box 4 ( <i>Pax4</i> )	15
1.3.7 Nierenberg and Kim 2 homeobox 2 ( <i>Nkx2.2</i> )	16
1.3.8 Nierenberg and Kim 6 homeobox 1 ( <i>Nkx6.1</i> )	16
1.3.9 Paired box 6 ( <i>Pax6</i> )	17
1.3.10 V-maf musculoaponeurotic fibrosarcoma oncogene homolog A ( <i>MafA</i> )	17

<b>1.4</b>	<b>Overview of T1D</b>	18
1.4.1	Aetiology and pathogenesis	18
1.4.2	Clinical features and complications of T1D	20
1.4.3	Current treatments for type I diabetes mellitus	20
1.4.3.1	Insulin therapy	20
1.4.3.2	Pancreas or islet transplantation	21
<b>1.5</b>	<b>Potential treatments for type T1D</b>	
1.5.1	Stem cell therapy	22
1.5.2	Gene therapy	23
<b>1.6</b>	<b>Vectors for gene therapy</b>	23
1.6.1	Retroviral and lentiviral vectors	25
1.6.2	Herpes simplex viral vectors	27
1.6.3	Adenoviral vectors and helper-dependent-adenoviral vectors	28
1.6.4	Recombinant adeno-associated viral vectors	29
<b>1.7</b>	<b>Target cells for T1D gene therapy</b>	31
<b>1.8</b>	<b>Liver-directed gene therapy</b>	33
<b>1.9</b>	<b>Aims of the project</b>	37
<b>Chapter 2: Material and Methods</b>		40
<b>2.1</b>	<b>Vector constructs</b>	41
2.1.1	HMD (lentiviral) vector	41
2.1.2	AAV8 and AAV8/piggyBac vector systems	41
<b>2.2</b>	<b>Animal housing conditions, monitoring and care</b>	44
2.2.1	Housing conditions	44
2.2.2	Animal monitoring and care	44
2.2.3	Intraperitoneal injection of AAV vectors	45
2.2.4	Intraperitoneal glucose tolerance test (IPGTT)	45
2.2.5	Pre-operative care, anaesthesia and monitoring	46
2.2.6	Intra-operative care, anaesthesia and monitoring	47
2.2.7	Post-operative care	48
<b>2.3</b>	<b>Tissue collection and storage</b>	49

<b>2.4</b>	<b>DNA extraction from mouse livers</b>	49
2.4.1	DNA extraction	49
2.4.2	Quality and quantity assessment of isolated DNA	50
<b>2.5</b>	<b>RNA extraction from mouse tissue</b>	50
2.5.1	RNA extraction	50
2.5.2	Quality and quantity assessment of isolated RNA	51
<b>2.6</b>	<b>Removal of DNA from RNA extract</b>	51
<b>2.7</b>	<b>Synthesis of complimentary DNA (cDNA) by reverse transcription</b>	52
<b>2.8</b>	<b>Preparation of DNA standards for quantitative polymerase chain reaction</b>	53
2.8.1	Preparing media for transformation and propagation of plasmids	54
2.8.2	Propagation of the AAV8-eGFP and pGEMTEZ-GAPDH plasmids	54
2.8.2.1	Bacterial transformation of AAV8-eGFP plasmids	54
2.8.2.2	Bacterial transformation of pGEMTEZ-GAPDH plasmids	54
2.8.2.3	Generation of the AAV8-eGFP and the pGEMTEZ-GAPDH plasmid clones	54
2.8.2.4	Plasmid preparation	54
2.8.2.5	Plasmid digestion and purification	55
<b>2.9</b>	<b>Polymerase chain reactions</b>	56
2.9.1	Oligonucleotide primers	56
2.9.2	Detection of target gene expression by reverse transcription polymerase chain reaction (RT-PCR)	60
2.9.3	RT-qPCR using SYBR Green	61
2.9.4	RT-qPCR using TaqMan assays	63
2.9.5	AAV8 vector copy number (VCN) quantitation by qPCR using SYBR Green	64

<b>2.10</b>	<b>Detection of the Reporter Fluorophores</b>	65
2.10.1	Slide fixation	65
2.10.2	Microscopic detection of fluorescent reporter fluorophores	65
<b>2.11</b>	<b>Statistical analysis</b>	66
<b>Chapter 3: Studying the effects of the AAV8 vectors transduction in STZ-induced diabetic NOD/scid mouse model</b>		66
<b>3.1</b>	<b>Introduction</b>	67
<b>3.2</b>	<b>Specific aims</b>	69
<b>3.3</b>	<b>Material and methods</b>	69
3.3.1	Inducing diabetes in NOD/scid mice using STZ	69
3.3.1.1	Preparation of STZ solution for injection	69
3.3.1.2	Inducing diabetes in NOD/scid mice by STZ injections	70
3.3.2	In vivo transduction	70
3.3.2	Quantitative PCR (qPCR) analysis of AAV8 vector copy number after transduction	71
3.3.4	Statistical analysis	72
<b>3.4</b>	<b>Results</b>	72
3.4.1	The transduction of STZ-induced diabetic NOD/scid mice with AAV8- <i>INS-FUR</i>	72
3.4.2	The transduction of STZ-induced diabetic NOD/scid mice with AAV8- <i>Pdx1</i>	75
3.4.3	The transduction of STZ-induced diabetic NOD/scid mice with AAV- <i>NeuroD1</i>	78
3.4.4	The transduction of STZ-induced diabetic NOD/scid mice with the combination of AAV8- <i>INS-FUR</i> and AAV8- <i>Pdx1</i>	81
3.4.5	The transduction of STZ-induced diabetic NOD/scid mice with the combination of AAV8- <i>INS-FUR</i> and AAV8- <i>NeuroD1</i>	84

3.4.6	Transduction of STZ-induced diabetic NOD/scid mice with the combination of AAV8- <i>INS-FUR</i> , AAV8- <i>Pdx1</i> and AAV8- <i>NeuroD1</i>	87
3.4.7	RT-PCR analysis of pancreatic gene expression in the transduced livers of the STZ-induced diabetic NOD/scid mice: Determining evidence of transdifferentiation	90
3.4.8	The transduction of STZ-induced diabetic NOD/scid mice with the combination of AAV8- <i>INS-FUR</i> and FFO surgery	92
<b>3.5</b>	<b>Discussion</b>	94
 <b>Chapter 4: Studying the effects of the AAV8 vector transduction in autoimmune non-obese-diabetic (NOD) mouse model</b>		97
4.1	<b>Introduction</b>	98
4.2	<b>Chapter conclusion</b>	115
 <b>Chapter 5: Transcriptome analysis of the NOD mouse livers transduced by AAV8-<i>INS-FUR</i></b>		116
5.1	<b>Introduction</b>	117
5.2	<b>Material and Methods</b>	118
5.3	<b>Results and discussion</b>	121
5.3.1	Summary of the microarray results	121
5.3.2	Pathways, diseases and biological functions and hepatotoxicity functions associated with the genes that were differentially expressed	127
5.3.2.1	Comparing the AAV group to the normal group	127
5.3.2.2	Comparing the AAV+FFO group to the normal group	133
5.3.2.3	Comparing the AAV+FFO group to the AAV group	138
5.3.3	Comparing the pathways of interest across the three groups of mice	143

5.3.3.1	The Adar1 editing deficiency immune response pathway	143
5.3.3.2	Glycolysis and gluconeogenesis	151
5.3.3.3	Glycogen metabolism pathway	157
5.3.4	Comparing the expression levels of the pancreatic genes of interest across all the experiments	161
<b>5.4</b>	<b>Conclusion and future directions</b>	<b>163</b>
 <b>Chapter 6: General discussions</b>		<b>165</b>
<b>6.1</b>	<b>The efficacy of the AAV8 vectors</b>	<b>166</b>
6.1.1	AAV8 delivery of INS-FUR and pancreatic transcription factor genes could not induce the partial liver to pancreas transdifferentiation	166
6.1.2	Transduction efficiency of the AAV8 vectors	169
<b>6.2</b>	<b>FFO surgery was insufficient in inducing the liver-to-pancreas transdifferentiation after the AAV8 transduction</b>	<b>170</b>
<b>6.3</b>	<b>The roles of the VSV-G capsid and the hybrid HIV/MSCV promoters of the HMD vector in the transdifferentiation</b>	<b>171</b>
<b>6.4</b>	<b>The efficacy of the AAV8/<i>piggyBac</i> vectors system in delivering the <i>INS-FUR</i> gene</b>	<b>172</b>
<b>6.5</b>	<b>Conclusion and future recommendation</b>	<b>173</b>
 <b>References</b>		<b>175</b>
 <b>Appendices</b>		<b>190</b>

# List of Figures and Tables

Figure	Page
1.1 Processing of bioactive insulin from its inactive precursor	5
1.2 The mechanism of insulin secretion.	6
1.3 Insulin induces cellular glucose uptake	7
1.4 The expression of pancreatic transcription factors at various stages of pancreatic $\beta$ -cell development	9
1.5 Speculated pancreatic $\beta$ -cell differentiation pathways	12
1.6 Immunological processes leading to pancreatic $\beta$ -cell dysfunction	19
2.1 Schematic representation of the AAV8 construct maps	43
3.1 Immunofluorescent detection of the marker gene venus in a liver of a representative diabetic NOD/scid mouse transduced by AAV8- <i>INS-FUR</i>	73
3.2 BGLs and body weights of diabetic NOD/scid mice transduced by AAV8- <i>INS-FUR</i> or AAV8- <i>venus</i>	74
3.3 AAV8 copy numbers in the livers of the diabetic NOD/scid mice transduced by AAV8- <i>INS-FUR</i>	75
3.4 AAV8 copy numbers in the livers of diabetic NOD/scid mice transduced by AAV8- <i>Pdx1</i>	76
3.5 BGLs and body weights of diabetic NOD/scid mice transduced by AAV8- <i>Pdx1</i>	77
3.6 Expression of the marker gene cerulean in a liver of a representative diabetic NOD/scid mouse transduced by AAV8- <i>NeuroD1</i>	79
3.7 BGLs and body weights of diabetic NOD/scid mice transduced by AAV8- <i>NeuroD1</i> or AAV8-cerulean	80
3.8 AAV8 copy numbers in the livers of diabetic NOD/scid mice transduced by AAV8- <i>NeuroD1</i>	81
3.9 Transgene copy numbers in the livers of the diabetic NOD/scid mice transduced by the combination of AAV8- <i>INS-FUR</i> and AAV8- <i>Pdx1</i>	82



<b>Figure</b>	<b>Page</b>
3.10 BGLs and body weights of diabetic NOD/scid mice transduced by the combination of AAV8- <i>INS-FUR</i> and AAV8- <i>Pdx1</i>	83
3.11 Transgene copy numbers in the livers of the diabetic NOD/scid mice transduced by the combination of AAV8- <i>INS-FUR</i> and AAV8- <i>NeuroD1</i>	84
3.12 Daily BGLs and weights of diabetic NOD/scid mice transduced by the combination of AAV8- <i>INS-FUR</i> and AAV8- <i>NeuroD1</i>	86
3.13 Transgene copy numbers in the livers of diabetic NOD/scid mice transduced by the combination of AAV8- <i>INS-FUR</i> , AAV8- <i>Pdx1</i> and AAV8- <i>NeuroD1</i>	88
3.14 BGLs and body weights of diabetic NOD/scid mice transduced by combinations of AAV8- <i>INS-FUR</i> , AAV8- <i>Pdx1</i> and AAV8- <i>NeuroD1</i>	89
3.15 RT-PCR detection of transgene and other pancreatic gene expression in the AAV8 transduced diabetic NOD/scid mouse livers	91
3.16 Weekly BGLs and weights of diabetic NOD/scid mice transduced by AAV8- <i>INS-FUR</i> and followed with FFO surgery	93
5.1 PCA mapping of the microarray datasets from the AAV8- <i>INS-FUR</i> -venous transduced and the normal livers of the NOD mice	122
5.2 Differential gene expression in the livers of the AAV- <i>INS-FUR</i> transduced NOD mice	123
5.3 The differential gene expression of the AAV group in comparison to the normal group	124
5.4 The differential gene expression of the AAV+FFO group in comparison to the normal group	125
5.5 The differential gene expression of the AAV+FFO group in comparison to the AAV group	126
5.6 The canonical pathways associated with the differential gene expression of the AAV group relatively to normal group	129
5.7 Canonical pathways associated with the differential genes of the AAV+FFO group relatively to the normal group	135

<b>Figure</b>	<b>Page</b>
5.8 Canonical pathways associated with the differentially expressed genes of the AAV+FFO group relatively to the AAV group	140
5.9 Differential expression of the genes in the Adar1 editing deficiency immune response pathway of the AAV group relatively to the normal group	147
5.10 Differential expression of the genes in the Adar1 editing deficiency immune response pathway of the AAV+FFO group relatively the normal group	148
5.11 Differential expression of the genes in the Adar1 editing deficiency immune response pathway of the AAV+FFO group relatively to the AAV group	150
5.12 Differential expression of genes in the glycolysis and gluconeogenesis pathways in the AAV group relatively to the normal group	153
5.13 Differential expression of the genes in the glycolysis and gluconeogenesis pathways in the AAV+FFO group relatively to the normal group	155
5.14 Differential expression of the genes in the glycolysis and gluconeogenesis pathways of the AAV+FFO group relatively to the AAV group	156
5.15 Differential expression of the genes involves in the glycogen metabolism pathways of the AAV group relatively to the normal group	158
5.16 Differential expression of the genes involves in the glycogen metabolism pathways of the AAV+FFO group relatively to the normal group	159
5.17 Differential expression of the genes involves in the glycogen metabolism pathways of the AAV+FFO group relatively to the AAV group	160

<b>Figure</b>	<b>Page</b>
6.1 Summary of the BGLs, IPGTTs and the expression of endogenous pancreatic genes in the livers of the NOD/scid and NOD mice transduced by AAV8 vectors	168

<b>Table</b>	<b>Page</b>
1.1 Roles of pancreatic transcription factors in $\beta$ -cells development	10
1.2 Characteristics of viral vectors used for gene therapy	24
2.1 List of AAV8 vector systems used in this research work	42
2.2 Reaction constituents for removal of contaminating genomic DNA from RNA samples by DNase digestion	52
2.3 Components of the Omniscript <sup>®</sup> Reverse Transcriptase reaction mixture	53
2.4 Components of the Tetro cDNA Synthesis Reverse Transcriptase reaction mixture	53
2.5 Restriction digest reaction components for digestion of the AAV8-LSP-eGFP plasmid	56
2.6 Components of the pGEMTEZ-GAPDH plasmid restriction reaction mixture	56
2.7 Sequences of primers used to amplify and quantitate the expression of the target genes of interest	58
2.8 Typical reaction constituents for PCR amplification reactions	60
2.9 RT-PCR amplification parameters	61
2.10 Components of the RT-qPCR reactions using the PowerUp <sup>™</sup> SYBRGreen <sup>®</sup> Master Mix qPCR reaction mixture	62
2.11 Fast RT-qPCR parameters for amplification using the PowerUp <sup>™</sup> SYBRGreen <sup>®</sup> Master Mix	62
2.12 Reaction components of RT-qPCR using TaqMan <sup>®</sup> Fast Advance Master Mix qPCR reaction mixture	63
2.13 RT-qPCR parameters for gene expression quantitation using the TaqMan <sup>®</sup> Fast Advanced Master Mix	64
2.14 Components of the RT-qPCR reactions using the PowerUp <sup>™</sup> SYBRGreen <sup>®</sup> Master Mix qPCR reaction mixture	65
3.1 Combinations of AAV8 vectors and dosages used in the liver transduction experiments	71

<b>Table</b>	<b>Page</b>
5.1 The top 20 pathways identified by the TAC program as being associated with the differential gene expression in the comparison between the AAV group and the normal group	128
5.2 Top 10 canonical pathways with positive z-score associated with the differential gene expression of the AAV group relatively to normal group	130
5.3 Canonical pathways with negative z-score associated with the differential gene expression of the AAV group relatively to normal group	130
5.4 The top 5 diseases and bio functions associated with the differentially expressed genes of the AAV group relatively to normal group	131
5.5 Comparison of hepatotoxicity functions between the AAV group and the normal group	133
5.6 The top 20 pathways identified by the TAC program as being associated with the differentially expressed genes of the AAV+FFO group relatively to the normal group	134
5.7 Pathways with positive z-score identified by the IPA program as being associated with the differentially expressed genes of the AAV+FFO group relatively to the normal group	165
5.8 Comparison of hepatotoxicity functions between the AAV+FFO group and the normal group	137
5.9 Top diseases and bio functions associated with the differentially expressed genes of the AAV+FFO in comparison to the normal group	138
5.10 The top 20 pathways identified by the TAC program as being associated with the differentially expressed genes of the AAV+FFO group relatively to the AAV group	139
5.11 The top 5 diseases and bio functions and bio functions associated with the differentially expressed genes of the AAV+FFO group relatively to the AAV group	141

<b>Table</b>	<b>Page</b>
5.12 Comparison of hepatotoxicity functions between the AAV+FFO group and the AAV group	142
5.13 Fold-changes in the expression levels of genes in the Adar1 editing deficiency immune response pathway	144
5.14 Fold-changes in the expression levels of pancreatic genes of interest and endogenous control genes	162

# List of Abbreviations

9330175E14Rik	RIKEN cDNA 9330175E14 gene
AAV	Recombinant adeno-associated virus
Ad	Adenovirus
Adar	adenosine deaminase, RNA-specific
Adar1	Double-stranded RNA-specific adenosine deaminase 1
AIHW	Australian Institute of Health and Welfare
APC	Antigen presenting cells
Apol9a	apolipoprotein L 9a
Apol9b	apolipoprotein L 9b
Arx	Aristaless related homeobox
ATP	Adenosine triphosphate
BGL	Blood glucose levels
bHLH	basic helix-loop-helix
B-H-p-value	Benjamini-Hochberg-P-value
Ca <sup>2+</sup>	Calcium ion
Ccl5	Chemokine (C-C motif) ligand 5
CD28	Cluster of Differentiation 28
CD40	Cluster of Differentiation 40
Cdc42	Cell division cycle 42
cDNA	Complementary deoxyribonucleic acid
CMRI	Westmead Children Medical Research Institute
CSII	Continuous subcutaneous insulin infusion
Cxcl10	chemokine (C-X-C motif) ligand 10
Cxcl11	chemokine (C-X-C motif) ligand 11
Ddx58	DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
Ddx60	DEAD (Asp-Glu-Ala-Asp) box polypeptide 60
Dhx58	DEXH (Asp-Glu-X-His) box polypeptide 58
DNA	Deoxyribonucleic acid
eGFP	Enhanced green fluorescent protein

ER	Endoplasmic reticulum
FAH	Fumarylacetoacetate hydroxylase
FDR	False detection rate
FFO	Full flow occlusion
Foxa2	Forkhead box A2
G6pc	Glucose-6-phosphatase catalytic
Gbp3	Guanylate binding protein 3
Gbp6	Guanylate binding protein 6
GDM	Gestational diabetes mellitus
GK	Glucokinase
GLUT2 (Slc2a2)	Glucose transporter 2
GLUT4 (Slc2a4)	Glucose transporter 4
Gm4951(Isg15)	predicted gene 4951
GPCRs	G protein coupled receptors
Gyg	Glucogenin
Gys2	Glycogen synthase 2
h	Hour
H4IIE/ND	Rat liver cell line (H4IIE) transfected with NeuroD1 gene
H4IIEins/ND	Rat liver cell line (H4IIE) transfected with INSFUR and NeuroD1 genes
HDAd	Helper-dependent adenoviral vector
HK3	Hexokinase3
HIV	Human immunodeficiency virus
HLAs	High-risk human leukocyte antigens
HMD/INSFUR	Lentiviral vector carrying INSFUR gene
HMGA2	AT-hook2 gene
HNF1	Hepatocyte Nuclear Factor 1
HNF6	Hepatocyte Nuclear Factor 6
HSV	Herpes simplex virus
IDF	International Diabetes Federation
Ifi44	Interferon-induced protein 44
Ifit1	Interferon-induced protein with tetratricopeptide repeats 1



Ifit3	Interferon-induced protein with tetratricopeptide repeats 3
IFN- $\gamma$	Interferon $\gamma$
Ikbke	Inhibitor of nuclear factor kappa B kinase subunit epsilon
Ikbkg	Inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
IL-1 $\beta$	Interleukin 1 $\beta$
<i>INS-FUR</i>	<i>Furin-cleavable insulin</i>
<i>i.p</i>	intraperitoneal
IPA	Ingenuity Pathway Analysis
IPCs	Insulin-producing-cells
IRF	Interferon regulator factor
Irf7	Interferon regulatory factor 7
Isg15	ISG15 ubiquitin-like modifier; Predicted gene 9706
ITRs	Inverted terminal repeats
kb	Kilobase
kg	Kilogram
Keap1-Nrf2	Kelch-like ECH-associated protein 1-nuclear factor (erythroid-derived 2)-like 2
LSP	Apolipoprotein E (ApoE) enhancer and the human $\alpha$ 1-antitrypsin (hAAT) promoter
LTRs	Long terminal repeats
Ly6a	Lymphocyte antigen 6 complex, locus A
Ly6c1	lymphocyte antigen 6 complex, locus C1; lymphocyte antigen 6 complex, locus C2
<i>MafA</i>	<i>V-maf musculoaponeurotic fibrosarcoma oncogene homolog A</i>
<i>MafB</i>	<i>V-maf musculoaponeurotic fibrosarcoma oncogene homolog B</i>
Map3k7	Mitogen-activated protein kinase 7
min	Minute
mRNA	Messenger ribonucleic acid
mmol	Millimole
MSCV	Mouse stem cell virus
Mx1	MX dynamin-like GTPase 1

Mx2	MX dynamin-like GTPase 2
<i>NeuroD1</i>	<i>Neuronal differentiation 1</i>
ng	nanogram
<i>Ngn3</i>	<i>Neurogenin3</i>
<i>Nkx2.2</i>	<i>Nierenberg and Kim 2 homeobox 2</i>
<i>Nkx6.1</i>	<i>Nierenberg and Kim 6 homeobox 1</i>
Nlrc5	NLR family, CARD domain containing 5
NOD	Non-obese diabetic
NOD/scid	Non-obese-diabetic/ severe combined immunodeficiency
NTBC	2-(2-nitro-4-trifluoro-methylbenzoyl) 1,3-cyclohexedione
Oas1a	2'-5' oligoadenylate synthetase 1A
Oas1l	2'-5' oligoadenylate synthetase-like 1
Oas12	2'-5' oligoadenylate synthetase-like 2
<i>Pax4</i>	<i>Paired box 4</i>
<i>Pax6</i>	<i>Paired box 6</i>
<i>PC1</i>	<i>Processing endopeptidase 1</i>
<i>PC2</i>	<i>Processing endopeptidase 2</i>
PCA	Principal component analysis
Pck1	Phosphoenolpyruvate carboxykinase 1, cytosolic gene
PCR	Polymerase chain reaction
<i>Pdx1</i>	<i>Pancreatic duodenal homeobox1</i>
PKR	Protein Kinase R
Pklr	Pyruvate kinase liver and red blood cell gene
Ptf1	Pancreatic specific transcription factor 1
Ptf1a (or P48)	Pancreatic specific transcription factor 1a
Rsad2	Radical S-adenosyl methionine domain containing 2
Rtp4	Receptor transporter protein 4
RT-PCR	Reverse transcriptase polymerase chain reaction
RT-qPCR	Quantitative reverse transcriptase polymerase chain reaction
SAP	Sensor augmented pump
<i>s.c</i>	Subcutaneous
SCID	Severe combined immunodeficiency

sec	Second
Sp100	Nuclear antigen Sp100
SPINK 2	Serine protease inhibitor Kazal-type 2
STZ	Streptozotocin
T1D	Type 1 diabetes
T2D	Type 2 diabetes
TAC	Transcriptome Analysis Console
Tgtp1	T cell specific GTPase 1
Tgtp2	T cell specific GTPase 2
Th1	T helper1
Th2	T helper 2
Tlr3	Toll-like receptor 3
Tu	Transduction unit
Usp18	Ubiquitin specific peptidase 18
VCN	Vector copy number
vg	Viral genome
VSV-G	Vesicular stomatitis virus envelope glycoprotein G
Wnt	Wingless-related integration site
Xaf1	XIAP associated factor 1
Zbp1	Z-DNA binding protein 1
$\alpha$ -cell	Alpha cell
$\beta$ -cell	Beta-cell
$\delta$ -cells	Delta-cell

# Abstract

Type I diabetes mellitus (T1D) is a chronic metabolic disorder resulting from the autoimmune attack and destruction of the pancreatic  $\beta$ -cells, leading to insulin deficiency and hyperglycaemia. The condition is currently managed by insulin therapy, which delays but does not fully prevent the long-term complications of the disease. The only cure for T1D is pancreas or islet transplantation; however, due to the lack of available organs and the complications from immunosuppression, transplantation is not widely applied. Gene therapy is one treatment being considered to treat and/ or cure T1D.

In earlier studies, our group delivered a lentiviral vector (HMD) carrying the furin-cleavable human insulin gene (*INS-FUR*) to streptozotocin (STZ)-induced diabetic rats, non-obese-diabetic mice, pancreatectomised diabetic pigs and humanized FRG mice using intervallic infusion of the vectors in full flow occlusion (FFO), a surgical technique that isolated the liver from the circulation. Reversal of diabetes with normal glucose tolerance and the expression of key  $\beta$ -cell transcription factors in the liver tissue of the transduced animals were achieved.

The main aim of the current study was to explore the possibility of reproducing the results of the HMD/*INS-FUR* transduction using less invasive transduction techniques. Traditional AAV8 vectors that have a higher tropism toward the hepatocytes were used to deliver the transgene *INS-FUR*, the  $\beta$ -cell transcription factors *Pdx1* or *NeuroD1*. The liver specific promoter (LSP) was also incorporated into the vector system to limit the expression of the transgene(s) to the livers and allow the vectors to be delivered by a simple intraperitoneal injection.

The expression of *Pdx1* or *NeuroD1* in the livers of the STZ-induced diabetic non-obese-diabetic and severe immune incompetent (NOD/scid) mice by the AAV8-LSP system did not cure diabetes. The delivery of the *INS-FUR* gene by AAV8-LSP led to hypoglycaemia in both STZ-induced diabetic NOD/scid mice and autoimmune non-obese-diabetic (NOD) mice. The transcriptome analysis of the livers of the NOD mice transduced by

AAV8-*INS-FUR* alone showed that severe hypoglycaemia that was observed in the animals may have been caused by an activation of the glycolysis pathway and an inhibition of the gluconeogenesis pathway. Using the same AAV8-LSP vector system to deliver *INS-FUR* with  $\beta$ -cell transcription factors (*Pdx1* and/ or *NeuroD1*) caused hypoglycaemia in diabetic NOD/scid mice, while the combination of *INS-FUR* and *Pdx1* was ineffective in treating diabetes in NOD mice. The combination of the AAV8-*INS-FUR* and FFO surgery or the empty HMD vector could not reverse diabetes in NOD mice either. In addition, the transcriptome analysis showed that the AAV8 transduction could also generate an antiviral immune reaction, but the AAV8 transduction with or without the FFO surgery may not cause any liver disease.

In this project the hybrid AAV8/*piggyBac* that could facilitate the integration of the transgene into the host genome was also used to deliver the *INS-FUR* gene. The hybrid system had both the transposon and *transposase* constructs of the *piggyBac* system incorporated into the AAV8-LSP vectors (AAV8/*piggyBac-INS-FUR*). The delivery of the *INS-FUR* gene by the AAV8/*piggyBac* could not normalise the random blood glucose levels in the NOD mice, but normal glucose tolerance was achieved. By comparison NOD mice that received FFO surgery after the AAV8/*piggyBac-INS-FUR* transduction had normal blood glucose levels, normal glucose tolerance and possibly glucose-responsive insulin secretion without the expression of any endogenous  $\beta$ -cell transcription factors. It was thought that the stable blood glucose levels were achieved because the FFO surgery may have helped to reduce the number of *transposases* and allowed a more stable integration of the *INS-FUR* gene to the host genome. In addition, the results suggested that the clinical desirable outcomes (normal blood glucose levels and glucose tolerance) could be achieved without the expression of  $\beta$ -cell transcription factors. This is the first *in vivo* study using the hybrid AAV8/*piggyBac* system to treat T1D. The study suggested that AAV8/*piggyBac* system may be further developed to become an alternative therapy for the disease.